Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)
- Creators
- Ferrandina G.
- Cynthia A.
- Raimondo B. P.
- Maria C. F. C.
- Paolo C.
- Francesca C.
- Nicoletta C.
- Alessandro C.
- CORVO' RENZO GIACINTO.
- Pierandrea D. I.
- Paolo D. T. A.
- Vittorio D.
- Marco F.
- Massimo F.
- Angiolo G.
- Alessandro G.
- Stefano G.
- Amato I.
- Franco O.
- Tommaso P.
- Vittorio Q.
- Roberta S.
- Carla T. A.
- Franco Z. G.
- Giovanni S.
- Domenica L.
- Others:
- Ferrandina, G.
- Cynthia, A.
- Raimondo, B. P.
- Maria, C. F. C.
- Paolo, C.
- Francesca, C.
- Nicoletta, C.
- Alessandro, C.
- CORVO' RENZO, Giacinto.
- Pierandrea, D. I.
- Paolo, D. T. A.
- Vittorio, D.
- Marco, F.
- Massimo, F.
- Angiolo, G.
- Alessandro, G.
- Stefano, G.
- Amato, I.
- Franco, O.
- Tommaso, P.
- Vittorio, Q.
- Roberta, S.
- Carla, T. A.
- Franco, Z. G.
- Giovanni, S.
- Domenica, L.
Description
Background: Uterine sarcomas are very rare tumours with different histotypes, molecular features and clinical outcomes; therefore, it is difficult to carry out prospective clinical trials, and this often results in heterogeneous management of patients in the clinical practice. Aim: We planned to set up an Italian consensus conference on these diseases in order to provide recommendations on treatments and quality of care in our country. Results: Early-stage uterine sarcomas are managed by hysterectomy + bilateral salpingo-oophorectomy according to menopausal status and histology; lymphadenectomy is not indicated in patients without bulky nodes, and morcellation must be avoided. The postoperative management is represented by observation, even though chemotherapy can be considered in some high-risk patients. In early-stage low-grade endometrial stromal sarcoma and adenosarcomas without sarcomatous overgrowth, hormonal adjuvant treatment can be offered based on hormone receptor expression. In selected cases, external beam radiotherapy ± brachytherapy can be considered to increase local control only. Patients with advanced disease involving the abdomen can be offered primary chemotherapy (or hormonal therapy in the case of low-grade endometrial stromal sarcoma and adenosarcoma without sarcomatous overgrowth), even if potentially resectable in the absence of residual disease in order to test the chemosensitivity (or hormonosensitivity); debulking surgery can be considered in patients with clinical and radiological response. Chemotherapy is based on anthracyclines ± ifosfamide or dacarbazine. Palliative radiotherapy can be offered for symptom control, and stereotactic radiotherapy can be used for up to five isolated metastatic lesions. Conclusions: Treatment of uterine sarcoma should be centralised at referral centres and managed in a multidisciplinary setting.
Additional details
- URL
- http://hdl.handle.net/11567/1028552
- URN
- urn:oai:iris.unige.it:11567/1028552
- Origin repository
- UNIGE